Search

Legend Biotech Corp ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

21.19 1.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

20.69

Max

21.7

Pagrindiniai rodikliai

By Trading Economics

Pajamos

88M

33M

Pardavimai

82M

388M

Pelnas, tenkantis vienai akcijai

0.09

Pelno marža

8.568

Darbuotojai

3,200

EBITDA

92M

60M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+129.56% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-11

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.9M

4B

Ankstesnė atidarymo kaina

19.56

Ankstesnė uždarymo kaina

21.19

Naujienos nuotaikos

By Acuity

100%

0%

326 / 340 reitingas Healthcare

Legend Biotech Corp ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-24 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, continuing a strong upward trend since Monday's close. The stock remains above its 20-day moving average.

2026-08-21 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, maintaining a position near the upper end of their one-month trading range.

2026-08-20 23:46; UTC

Legend Biotech Corp. shares are trading higher in after-market hours, diverging from broader market pressures amid rising crude oil prices and geopolitical tensions.

2026-08-19 23:01; UTC

Legend Biotech Corp shares are higher in after-market trading, showing notable strength and exceeding the 20-day moving average. No specific news was identified.

2026-08-18 20:03; UTC

Social Media

Legend Biotech Corp shares are higher today, buoyed by strong investor sentiment and analyst confidence in significant upside potential for the stock.

2026-08-14 19:36; UTC

Shares of Legend Biotech Corp are trading higher, though fluctuations have been routine during the session. The stock remains below its 20-day moving average.

2026-08-13 23:21; UTC

Legend Biotech Corp shares are higher in after-market hours, gaining traction following notable trading activity after Thursday's close. No specific news was identified.

2026-08-12 23:16; UTC

Legend Biotech Corp. shares are higher in after-market hours, reflecting positive market conditions amid a Consumer Price Index report that met forecasts.

2026-08-11 23:46; UTC

Shares of Legend Biotech Corp are higher in after-market hours, maintaining a position above the 20-day moving average amid stable trading conditions.

2026-08-10 23:06; UTC

Shares of Legend Biotech are higher in after-market trading, settling above Monday's close despite mixed market sentiment and geopolitical tensions.

2026-08-07 23:46; UTC

Shares of Legend Biotech Corp traded higher in after-market hours, amid a broader market context of a declining unemployment rate.

2026-08-06 20:06; UTC

Legend Biotech Corp shares are higher today, reflecting a shift from recent trends. No specific company news was identified to explain this movement.

2026-08-04 19:36; UTC

Legend Biotech Corp shares are higher today, recovering from an earlier low. Positive momentum persists despite a decline in U.S. core factory orders.

2026-08-03 22:01; UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

2026-07-31 23:56; UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

2026-07-30 22:41; UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

2026-07-29 19:27; UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

2026-07-28 22:56; UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

2026-07-27 23:16; UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

2026-07-24 19:16; UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

2026-07-22 18:31; UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

2026-07-21 16:46; UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

2026-07-20 19:01; UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Akcijų palyginimas

Kainos pokytis

Legend Biotech Corp ADR Prognozė

Kainos tikslas

By TipRanks

129.56% į viršų

12 mėnesių prognozė

Vidutinis 48.07 USD  129.56%

Aukščiausias 78 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Legend Biotech Corp ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

6

Pirkti

4

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.
help-icon Live chat